DENVER, CO–(Marketwired – Aug 7, 2013) – ViroCyt, LLC, the leader in the field of rapid virus quantification, disclosed today the addition of two new distributors to its growing international network. Biotech Europe will sell and support ViroCyt’s Virus Counter in Central and Eastern Europe (CEE) as well as the Commonwealth of Independent States (CIS). CESCO Bioengineering Ltd. will address the emerging Taiwanese market. Said Robert Kline, ViroCyt President & CEO, “By bringing Biotech Europe and CESCO on board, we now have a significant presence throughout Europe and Asia. Both regions are experiencing marked growth in the life science space, and we see substantial opportunity for the Virus Counter.”
The Virus Counter 2100 is a compact, bench-top instrument that enables total intact virus particles to be quantified in minutes, rather than the days or weeks required by traditional methods. This allows samples to be taken directly from cell- or egg-based growth systems and immediately assayed, providing viral titers in real time. By utilizing the Virus Counter, companies, institutes and university researchers around the world that develop and produce vaccines and biologics are recognizing significant time and cost savings.
According to Igor Valerian, Business Director of BioTech a.s., “We saw the unique value the Virus Counter provides and are excited to be the sole source of the product in the CEE and CIS markets. We’ve established ourselves as a leading provider of innovative solutions for the life science community, and the Virus Counter is an outstanding addition to our portfolio. There is truly nothing else like it out there.”
Added King-Ming Chang, Chief Research Officer of CESCO Bioengineering, “Over the past decade, Taiwan has seen remarkable growth of its biotechnology industry, and we felt the time was right to partner with ViroCyt to bring the Virus Counter here. Instant, reliable virus counting has long been a critical missing piece in biotechnology, especially in vaccine industry. We believe that integrating the Virus Counter with our cell culture technology portfolio will offer a more comprehensive solution to our pharmaceutical clients. The creation of life-saving vaccines and drugs, especially against emerging viral diseases, is of paramount importance, and the Virus Counter has demonstrated the ability to improve these processes. We are very glad to work with ViroCyt with this novel product and thereby transform bioindustry into a new era.”
About Biotech Europe
Established in 1997 as the cooperative partner of research, clinical and industrial laboratories, BioTech is the European leader in the supply of instruments, reagents and consumables for the life science industry. Our main focus is the delivery, technical and application support of high tech, state of the art instruments. Headquartered in the heart of Europe — Prague, Czech Republic — with several branch offices, BioTech has developed a system of quick response to all possible customers needs. For more information, go to http://www.biotech-europe.eu.
About CESCO Bioengineering
CESCO Bioengineering Co., Ltd. Taiwan, R.O.C. is a dynamic, innovative and scientifically-motivated company focused on cell culture bioprocess technology development by providing novel solutions for customers from early research to manufacture. CESCO delivers the capability to develop and integrate novel bioprocess products including cell culture bioreactors, culture medium formulation, cell culture carriers, biosensors, bioprocess mixing tanks and containers. It demonstrates our ambitions to serve customers as a one-stop-shop solution to save their time and cost on process development as well as manufacturing. To learn more, visit http://www.cescobio.com.tw.
ViroCyt, LLC was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at http://www.virocyt.com.
Original Article: http://www.marketwire.com/press-release/ViroCyt-Increases-Global-Reach-1818421.htm